Compare AANJANEYA LIFECARE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS AJANTA PHARMA DR. DATSONS LABS/
AJANTA PHARMA
 
P/E (TTM) x -10.9 22.3 - View Chart
P/BV x 0.2 3.8 4.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 DR. DATSONS LABS   AJANTA PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
AJANTA PHARMA
Mar-19
DR. DATSONS LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,422 8.8%   
Low Rs31898 3.4%   
Sales per share (Unadj.) Rs133.0233.5 57.0%  
Earnings per share (Unadj.) Rs0.244.0 0.3%  
Cash flow per share (Unadj.) Rs6.652.2 12.7%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs128.8255.1 50.5%  
Shares outstanding (eoy) m31.6688.02 36.0%   
Bonus/Rights/Conversions FCCBBB-  
Price / Sales ratio x0.65.0 11.8%   
Avg P/E ratio x516.126.4 1,956.5%  
P/CF ratio (eoy) x11.822.2 53.3%  
Price / Book Value ratio x0.64.5 13.4%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m2,477102,081 2.4%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m564,307 1.3%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m4,21120,554 20.5%  
Other income Rs m79211 37.3%   
Total revenues Rs m4,28920,765 20.7%   
Gross profit Rs m5695,664 10.0%  
Depreciation Rs m204721 28.4%   
Interest Rs m43012 3,708.6%   
Profit before tax Rs m135,143 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m61,273 0.5%   
Profit after tax Rs m53,870 0.1%  
Gross profit margin %13.527.6 49.0%  
Effective tax rate %48.024.8 194.0%   
Net profit margin %0.118.8 0.6%  
BALANCE SHEET DATA
Current assets Rs m6,85211,812 58.0%   
Current liabilities Rs m6,7113,776 177.7%   
Net working cap to sales %3.339.1 8.6%  
Current ratio x1.03.1 32.6%  
Inventory Days Days16177 207.9%  
Debtors Days Days31882 390.3%  
Net fixed assets Rs m3,67314,398 25.5%   
Share capital Rs m317175 180.5%   
"Free" reserves Rs m3,76122,277 16.9%   
Net worth Rs m4,07822,452 18.2%   
Long term debt Rs m1,6717 25,315.2%   
Total assets Rs m12,63326,962 46.9%  
Interest coverage x1.0444.3 0.2%   
Debt to equity ratio x0.40 139,393.8%  
Sales to assets ratio x0.30.8 43.7%   
Return on assets %3.414.4 23.9%  
Return on equity %0.117.2 0.7%  
Return on capital %7.723.0 33.4%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96410,682 9.0%   
Fx outflow Rs m6072,102 28.9%   
Net fx Rs m3578,580 4.2%   
CASH FLOW
From Operations Rs m1,3453,748 35.9%  
From Investments Rs m-2,256-2,228 101.2%  
From Financial Activity Rs m-1,200-1,475 81.4%  
Net Cashflow Rs m-2,11145 -4,669.7%  

Share Holding

Indian Promoters % 4.5 73.8 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 1.4 7.6 17.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 17.0 553.5%  
Shareholders   20,807 20,968 99.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  PIRAMAL ENTERPRISES  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - TTK HEALTHCARE COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS